N-(1-azabicyclo[2.2.2]octan-3-yl)-4-chloro-1H-indole-2-carboxamide;5-chloro-1H-indole-2-carboxylic acid
C25H24Cl2N4O3 — CID 159630256
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-(1-azabicyclo[2.2.2]octan-3-yl)-4-chloro-1H-indole-2-carboxamide;5-chloro-1H-indole-2-carboxylic acid
N-(1-azabicyclo[2.2.2]octan-3-yl)-4-chloro-1H-indole-2-carboxamide;5-chloro-1H-indole-2-carboxylic acid (PubChem CID 159630256) has the molecular formula C25H24Cl2N4O3 and a molecular weight of 499.40 g/mol. Its IUPAC name is N-(1-azabicyclo[2.2.2]octan-3-yl)-4-chloro-1H-indole-2-carboxamide;5-chloro-1H-indole-2-carboxylic acid.
Molecular Properties
| Compound Name | N-(1-azabicyclo[2.2.2]octan-3-yl)-4-chloro-1H-indole-2-carboxamide;5-chloro-1H-indole-2-carboxylic acid |
|---|---|
| PubChem CID | 159630256 |
| Molecular Formula | C25H24Cl2N4O3 |
| Molecular Weight | 499.40 g/mol |
| Exact Mass | 498.12 |
| IUPAC Name | N-(1-azabicyclo[2.2.2]octan-3-yl)-4-chloro-1H-indole-2-carboxamide;5-chloro-1H-indole-2-carboxylic acid |
| SMILES | O=C(NC1CN2CCC1CC2)c1cc2c(Cl)cccc2[nH]1.O=C(O)c1cc2cc(Cl)ccc2[nH]1 |
| InChI | InChI=1S/C16H18ClN3O.C9H6ClNO2/c17-12-2-1-3-13-11(12)8-14(18-13)16(21)19-15-9-20-6-4-10(15)5-7-20;10-6-1-2-7-5(3-6)4-8(11-7)9(12)13/h1-3,8,10,15,18H,4-7,9H2,(H,19,21);1-4,11H,(H,12,13) |
| InChIKey | MPAKAWLUGMMIPY-UHFFFAOYSA-N |
| XLogP | 5.16 |
| TPSA | 101.22 Ų |
| H-Bond Donors | 4 |
| H-Bond Acceptors | 3 |
| Rotatable Bonds | 3 |
| Heavy Atoms | 34 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 499.40 |
| LogP ≤ 5 | 5.16 |
| H-Bond Donors ≤ 5 | 4 |
| H-Bond Acceptors ≤ 10 | 3 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 159630256 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.